Sign in to view content

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M. Brown, MD

Video
Published 2021

Related

Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in YOSEMITE/RHINE Phase 3 Studies
Barbara A. Blodi, MD
Annual Meeting Talks
2025

Category: Pharmacology

See more